UAE Investors Eye $39.4B GLP-1 Market Amid Healthcare Weakness


UAE investors focus on the GLP-1 obesity drug market, projected to reach USD 39.4 billion in 2026, as healthcare equities diverge and selective stock-picking rises.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin